Watch More Highlights
Tiffany Richards, PhD, ANP-BC, AOCNP®, of The University of Texas MD Anderson Cancer Center, dives into an analysis of minimal residual disease (MRD) negativity from a phase 1/2 trial in t(11;14)-positive relapsed/refractory multiple myeloma. The combination of venetoclax, daratumumab, and dexamethasone showed higher rates of MRD negativity compared with the combination of bortezomib, daratumumab, and dexamethasone (38% vs. 8%; Abstract 338).